Spear Bio Co-founder and CTO to present at Vaccine Summit

NAB-Sure ™, the new cell-free SARS-CoV-2 neutralizing antibody assay will be featured at Vaccine Summit in Washington D.C.

PRESS RELEASE

Woburn, MA, October 11 2022 – Feng Xuan, Spear Bio’s Co-Founder and chief technology officer, will share insightful research and results featuring NAB-Sure™ – a new, ultrasensitive immunoassay – during the Vaccine Summit 2022.  His presentation will focus on how the breakthrough Successive Proximity Extension Amplification Reaction (SPEAR) Technology can aid the evaluation of SARS-CoV-2 vaccines as the virus continues to evolve.

Vaccines were critical to managing the COVID-19 pandemic.  However, as the virus continues to evolve, these vaccines need to be re-evaluated and adapted for the latest variants.   An on-going validation effort need consistent, easily deployed methods to measure the humoral immune response to vaccines and treatments.  Dr. Feng Xuan’s presentation will provide industry leaders and researchers data and insights into how NAB-Sure™ can standardize these critical studies.

The Vaccine Summit takes place October 11-13 in the Washington DC area.  It is focused on next generation vaccine treatment and diagnostics that save lives.   “NAB-Sure™ SARS-CoV-2 Neutralizing Antibody Test Kit is just one way our technology can contribute to vaccine validation, and we are excited to join industry leaders and collaborate on the next generation of vaccine development,” said Dr. Xuan.

 

Vaccine Summit 2022

Title: “A Novel Ultrasensitive Cell-Free SARS-CoV-2 Neutralizing Antibody Assay for Measuring Humoral Immune Response of Vaccine with High Lab-To-Lab Consistency”

Presenter: Dr. Feng Xuan

Date: Thursday, October 13, 2022

Time: 2:20PM ET

Location: Sheraton Reston Hotel, Reston VA

 

Learn more about Vaccine Summit 2022 at www.scientiameetings.com/conferences/vaccines/

 

For More Information Contact: Oliver Tassinari, Sr. Director, Business Development, info@spear.bio

About Spear Bio

Spear Bio (www.spear.bio), founded in 2021 by Harvard researchers at the Wyss Institute, is headquartered in Woburn, MA. The company is devoted to the next generation of ultrasensitive immunoassay technology and collaborates closely with academic researchers, clinicians, and industry to develop more ultrasensitive detection approaches in support of clinical research, non-invasive sample collection methods, and cutting-edge laboratory diagnostics.

Visit www.spear.bio to learn more about our innovative approach to protein detection. Fill out the contact form to learn more and how to partner with Spear Bio on future innovations.

 

Posted Under: Press